GENOR BIOPHARMA DL-00002 (F:67N0) — Stock Price
GENOR BIOPHARMA DL-00002 (F:67N0) is currently trading at €0.18 EUR, up 7.74% today. Over the past 52 weeks, shares have ranged between €0.17 and €0.57. This page tracks GENOR BIOPHARMA DL-00002's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of GENOR BIOPHARMA DL-00002.
GENOR BIOPHARMA DL-00002 (67N0) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GENOR BIOPHARMA DL-00002's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
GENOR BIOPHARMA DL-00002 Income Statement — Revenue, Profit & Earnings by Year
GENOR BIOPHARMA DL-00002's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €206.23 Million | €0.00 | €15.93 Million | €0.00 |
| Cost of Revenue | €1.34 Million | €0.00 | €983.00K | €0.00 |
| Gross Profit | €204.89 Million | €0.00 | €14.95 Million | €0.00 |
| Research & Development | €202.78 Million | €564.28 Million | €583.88 Million | €612.72 Million |
| SG&A | €71.71 Million | €125.24 Million | €217.27 Million | €305.95 Million |
| Total Operating Expenses | €238.98 Million | €685.82 Million | €802.14 Million | €918.67 Million |
| Operating Income | €-32.75 Million | €-685.82 Million | €-786.21 Million | €-918.67 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €112.00K | €888.00K | €2.86 Million | €2.36 Million |
| Income Before Tax | €-35.13 Million | €-677.50 Million | €-732.42 Million | €-866.31 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-51.28 Million | €-674.36 Million | €-730.21 Million | €-865.22 Million |
GENOR BIOPHARMA DL-00002 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GENOR BIOPHARMA DL-00002's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €1.29 Billion | €1.45 Billion | €2.12 Billion | €2.86 Billion |
| Total Current Assets | €1.07 Billion | €1.24 Billion | €1.72 Billion | €2.39 Billion |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | — | — | — | — |
| Inventory | €0.00 | €5.67 Million | €47.40 Million | €49.65 Million |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | €17.82 Million | €17.82 Million | €21.75 Million | €21.75 Million |
| Total Liabilities | €138.05 Million | €256.18 Million | €309.87 Million | €369.73 Million |
| Total Current Liabilities | €122.09 Million | €229.53 Million | €260.39 Million | €313.19 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | — | — | — | — |
| Total Stockholder Equity | €1.15 Billion | €1.19 Billion | €1.80 Billion | €2.49 Billion |
| Retained Earnings | €-6.84 Billion | €-6.79 Billion | €-6.12 Billion | €-5.39 Billion |
GENOR BIOPHARMA DL-00002 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GENOR BIOPHARMA DL-00002 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | €-121.98 Million | €-425.12 Million | €-577.61 Million | €-623.74 Million |
| Capital Expenditures | €1.57 Million | €1.03 Million | €12.96 Million | €71.39 Million |
| Free Cash Flow | €-123.55 Million | €-426.15 Million | €-590.56 Million | €-695.13 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | — | — | — | — |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | €11.64 Million | €60.91 Million | €48.24 Million | €123.69 Million |
| Depreciation | €18.22 Million | €76.89 Million | €53.68 Million | €60.74 Million |
| Change in Cash | €-115.53 Million | €-425.95 Million | €-647.94 Million | €-660.43 Million |
GENOR BIOPHARMA DL-00002 Earnings History — EPS Actual vs. Analyst Estimates
Track GENOR BIOPHARMA DL-00002's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 26, 2026 | — | — | — |
| Aug 26, 2025 | — | — | — |
| Mar 25, 2025 | — | — | — |